109 related articles for article (PubMed ID: 15784241)
1. Validation of the anti-factor IIa assay and potency assessment of enoxaparin in pharmaceutical formulations.
Dalmora SL; Junior LB; Vaccari SF; Fronza M; Renato de Oliveira P; Rolim CM
Farmaco; 2005 Mar; 60(3):225-9. PubMed ID: 15784241
[TBL] [Abstract][Full Text] [Related]
2. Validation of the anti-factor Xa assay for the potency assessment of enoxaparin in pharmaceutical formulations.
Dalmora SL; Júnior LB; Schmidt CA; Vaccari SF; Oliveira PR; Codevilla CF
J AOAC Int; 2004; 87(6):1305-8. PubMed ID: 15675440
[TBL] [Abstract][Full Text] [Related]
3. Validation of the antifactor Xa and antifactor IIa assays for the potency assessment of nadroparin in pharmaceutical formulations.
Dalmora SL; da Silva Sangoi M; Barth T; Brum L; Vaccari SF
J AOAC Int; 2006; 89(1):58-64. PubMed ID: 16512229
[TBL] [Abstract][Full Text] [Related]
4. Reproducibility of the anti-Factor Xa and anti-Factor IIa assays applied to enoxaparin solution.
Martinez C; Savadogo A; Agut C; Anger P
J Pharm Biomed Anal; 2013; 81-82():138-45. PubMed ID: 23644908
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
Feng L; Shen-Tu J; Liu J; Chen J; Wu L; Huang M
Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
[TBL] [Abstract][Full Text] [Related]
6. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Bara L; Planes A; Samama MM
Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
[TBL] [Abstract][Full Text] [Related]
7. New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin.
Martínez-González J; Rodríguez C
Expert Rev Cardiovasc Ther; 2010 May; 8(5):625-34. PubMed ID: 20450295
[TBL] [Abstract][Full Text] [Related]
8. The establishment and validation of efficient assays for anti-IIa and anti-Xa activities of heparin sodium and heparin calcium.
Suzuki T; Ishii-Watabe A; Hashii N; Nakagawa Y; Takahashi T; Ebisawa A; Nishi S; Fujita N; Bando A; Sekimoto Y; Miyata K; Endo T; Otsu T; Sugimoto S; Kondou T; Fujita Y; Miyanaga N; Mashimo M; Shimada N; Yoden H; Shimamura H; Kurata Y; Koyama S; Kawasaki N
Biologicals; 2013 Nov; 41(6):415-23. PubMed ID: 24095600
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antithrombotic activity of two heparin fragments PK 10169 (mol. wt. 5,000) and EMT 680 (mol. wt. 2,500) and unfractionated heparin in a rabbit experimental thrombosis model: relative importance of systemic anti-Xa and anti-IIa activities.
Bara L; Trillou M; Mardiguian J; Samama M
Nouv Rev Fr Hematol (1978); 1986; 28(6):355-8. PubMed ID: 3562219
[TBL] [Abstract][Full Text] [Related]
10. Variability of plasma anti-Xa activities with different lots of enoxaparin.
Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
[TBL] [Abstract][Full Text] [Related]
11. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
12. Factor Xa is a superior target to factor IIa for antithrombotic therapies.
Büller HR
Semin Thromb Hemost; 2003 Dec; 29 Suppl 1():37. PubMed ID: 14730477
[No Abstract] [Full Text] [Related]
13. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
14. A novel point-of-care assay for the monitoring of low-molecular weight heparins in the cardiac catheterization laboratory.
Marmur JD; Lakhani M; El Rouby S; Cavusoglu E
J Invasive Cardiol; 2008 Sep; 20(9):449-54. PubMed ID: 18762674
[TBL] [Abstract][Full Text] [Related]
15. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
[TBL] [Abstract][Full Text] [Related]
16. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
[TBL] [Abstract][Full Text] [Related]
17. Comparison of anticoagulant and anti-inflammatory responses using enoxaparin versus unfractionated heparin for transesophageal echocardiography-guided cardioversion of atrial fibrillation.
Hoppensteadt D; Fareed J; Klein AL; Jasper SE; Apperson-Hansen C; Lieber EA; Katz WE; Malouf JF; Stoddard MF; Pape LA;
Am J Cardiol; 2008 Oct; 102(7):842-6. PubMed ID: 18805108
[TBL] [Abstract][Full Text] [Related]
18. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies on branded enoxaparin and a US generic version of enoxaparin.
Walenga JM; Jeske WP; Hoppensteadt D; Cunanan J; Khan H; Escalante V; Fareed J; Bakhos M
Clin Appl Thromb Hemost; 2013 Jun; 19(3):261-7. PubMed ID: 23091283
[TBL] [Abstract][Full Text] [Related]
20. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.
Martínez-González J; Vila L; Rodríguez C
Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):793-802. PubMed ID: 18570617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
